Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

g. OGX-427 is designed to reduce levels of Hsp27, a heat shock protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy, and radiation therapy. Results demonstrated that OGX-427 was safe and well tolerated as monotherapy, as well as in combination with docetaxel. In addition, when OGX-427 was used as a single agent there were declines in circulating tumor cells in patients at all doses and in all diseases evaluated, as well as evidence of reduction in tumor markers in prostate and ovarian cancer. - Partnering discussions and assessment of other opportunities to expand the development plan into additional randomized Phase 2 trials will continue. - A Phase 1 trial in bladder cancer is currently underway. - A randomized Phase 2 trial in CRPC is expected to initiate later this year.

Financial Results

Under our Collaboration Agreement with Teva relating to our contribution to the custirsen Phase 3 development plan, we earned Collaboration Revenues of $1.7 million and $6.4 million, respectively, for the three and six months ended June 30, 2010, compared to no revenues in the corresponding periods of 2009. Of the revenues in the second quarter, $362 thousand is reimbursable from Teva on a cash basis and is included on the Company's balance sheet as amounts receivable at June 30, 2010. As of June 30, 2010, $24.1 million of the upfront payment received from Teva was included on the Company's balance sheet as deferred collaboration revenue which we are amortizing over the expected performance period of our del
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... studies characterizing the analgesic profiles of a series ... receptor agonist molecules. The preclinical research candidates were ... platform. The analgesic properties of kappa ... literature. 1,2 Kappa opioid receptors are expressed ...
(Date:9/19/2014)... 2014 Cereal grain scientists, quality ... gather October 5–8, 2014, for the AACC International ... Center in Providence, Rhode Island. The comprehensive scientific ... food scientists, chemists, microbiologists, nutritionists, and those interested ... management. To date, 1,000 attendees have registered for ...
(Date:9/18/2014)... 2014 Bipartisan passage this week by ... to stimulate development and commercialization of new technologies and ... leaders of SPIE, the international society for optics ... and Innovation (RAMI) Act, now moves to the full ... they are optimistic that it will win passage there ...
(Date:9/18/2014)... A novel robotic system that can ... currently being tested as part of a biomedical research ... with the aim of determining if the robot, in ... biopsies faster, more accurate, less costly, and less discomforting ... potential to deliver prostate cancer therapies with greater precision. ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... Inc. (Nasdaq: ONXX ) today announced that ... Conference on Thursday, June 26, at,10:45 a.m. Eastern ... of,the presentation on our website at:, ... log on 15 minutes early in order to,register ...
... June 19 A new chemical fertility control,technology ... on rice production in developing countries is being ... Diego, California from the 17th,through the 20th of ... is developing a technology that will target the ...
... AstraZeneca,s CEO to be Deposed in London on Friday, ... Weitz & Luxenberg, PC, one of the,leading plaintiffs, litigation ... giant AstraZeneca on behalf of a New York City ... AstraZeneca,s drug Seroquel. The plaintiff, EMT Ernest Armstead, was ...
Cached Biology Technology:Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages 2Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages 3Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca 2
(Date:9/18/2014)... researchers from McGill University and the Quebec government ... ,microbeads, Canadian Journal of Fisheries and Aquatic ... cosmetics, household cleansers, or industrial cleansers, to which ... their small size and buoyancy, they may readily ... a global contaminant in the world,s oceans, but ...
(Date:9/18/2014)... MADISON, Wis. No matter how many times ... as social, communicating creatures. , But by ... single-celled organisms radically alter their behavior to suit ... many of them are present, and act accordingly. ... the millions, it may change from innocuous to ...
(Date:9/18/2014)... spoken language is unique to humans. "The genetic changes ... human evolution to make this possible are largely unknown, ... have," says Wolfgang Enard, Professor of Anthropology and Human ... molecular biological basis of language Enard has now taken ... study, undertaken in collaboration with scientists at several universities, ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... In the minds of many, Miscanthus x giganteus ... for lignocellulosic bioenergy production. But researchers believe "putting all their ... at the University of Illinois recently reported the first natural ... in Japan. "If M. x giganteus ...
... announced the winners of its second annual CPOW travel ... at the Baltimore Convention Center in Baltimore, Maryland, March ... for Women, has initiated these travel fellowships to increase ... at the Meeting. The recipients of this competitive ...
... The Biophysical Society has announced the winner of ... 55th Annual Meeting at the Baltimore Convention Center in ... meant to encourage participation at the Biophysical Society Annual ... will be honored at a reception on Saturday March ...
Cached Biology News:New Miscanthus hybrid discovery in Japan could open doors for biofuel industry 2New Miscanthus hybrid discovery in Japan could open doors for biofuel industry 3Biophysical Society announces winners of 2011 CPOW Travel Awards 2Biophysical Society announces winners of 2011 Minority Travel Awards 2
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
Request Info...
The BD OptEIA Rat TNF-alpha ELISA Kit is for the quantitative determination of TNF-alpha in rat serum, plasma and cell culture supernatant....
Biology Products: